MarketResearchReports.Biz
announces addition of new report"
RORgamma Modulators 2016: A comparative analysis of the landscape of
RORgamma antagonists and agonists "to
its database.
MarketResearchReports.biz
has announced that it now carries a report titled, ‘RORgamma
Modulators 2016:
A Comparative Analysis Of The Landscape Of RORgamma Antagonists And
Agonists.’ The report, prepared by a team of experts in the field,
will serve as tool that enables companies with business interests in
this area to make better informed decisions.
RAR-related
orphan receptor gamma (ROR?) is classified as a protein and it is
encoded by the gene, RAR-related orphan receptor C, which is
abbreviated as RORC. The present report delves upon the following
factors: the target RORgamma, the up-side indications and clinical
lead, various drug delivery strategies being deployed in this field,
the entire timeline of R&D programs ranging from the screening
state to first-in-human tests, as well as programs of un-partnered
pharmaceutical companies.
The
report begins with an introduction to RORgamma and then offers
insight into the target background. Following this, the report moves
on to details about target validation as well as approaches and
technologies used for drug discovery. On the target validation front,
the report gives readers detailed information pertaining to instances
where clinical success has been reported in anti-IL17 antibodies,
target validations that are non-clinical in nature, clinical lead
indication pertaining to RORgamma antagonists, and potential safety
concerns.
Download Sample copy of this
Report at http://www.marketresearchreports.biz/sample/sample/556098
A
comprehensive review of the competitive landscape that has developed
in the RORgamma modulators market over the years forms an especially
important aspect of the report. This section helps stakeholders
understand which companies have secured a competitive advantage in
the market and what that advantage exactly is. Based on their
end-use, the market report studies the RORgamma antagonists for
inflammatory as well as autoimmune diseases of various types. The
report also studies the same for cancer treatment therapeutics.
According
to the report, over 30 companies are currently actively engaged in
drug discovery as well as development. There are a few companies that
boast expertise on the technology that helps discover drugs that work
on nuclear hormone receptors. It is such companies that have had a
chance to partner with large biotech companies and those in the Big
Pharma league. The chances of securing such a partnership spike
higher if these technology companies have been successful in
identifying novel scaffolds pertaining to RORgamma antagonists.
The
report estimates that the market currently has over 10 such
partnerships between tech and pharma companies. The success rate of
such partnerships has not been disappointing, the report further
states. According to the report, three examples of RORgamma
antagonists are already reported to be under clinical development.
More such developments are expected to be seen in 2016 and beyond.
Comprising
88 pages, the report also features as many as 16 tables to make for
an easy-to-read format.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment